HepaRegeniX is developing drugs for treating acute and chronic liver diseases.
Heparegenix has raised €11M across 1 funding round, most recently a Series B round in Jan 2020. Based in Ulm, Germany; founded 2015; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2020-01-21 | Series B | €11M |
| — |
| View deal → |
